We are live on ! Find out more
RVPHW

Reviva Pharmaceuticals Warrants
RVPHW

Delisted

RVPHW was delisted on the 12th of December, 2025.

Back to rankings

14 hedge funds and large institutions have $3.97M invested in Reviva Pharmaceuticals Warrants in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

12% less capital invested

Capital invested by funds: $4.51M → $3.97M (-$542K)

18% less funds holding

Funds holding: 17 → 14 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
14
Holders Change
-3
Holders Change %
-17.65%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
3
Closed
3
Calls
$31K
Puts
–
Net Calls
+$31K
Net Calls Change
+$31K

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$36.7K
2
UBS Group
UBS Group
Switzerland
+$2.62K
3
Walleye Trading
Walleye Trading
New York
+$1.45K
4
Walleye Capital
Walleye Capital
New York
+$650

Top Sellers

Rank Fund Capital Flow
1
BCM
Basso Capital Management
Connecticut
-$40K
2
BCM
Bluefin Capital Management
New York
-$33.6K
3
BFM
Boothbay Fund Management
New York
-$26.8K
4
GCIA
Gabelli & Co Investment Advisers
New York
-$22.7K
5
GCL
Glazer Capital LLC
New York
-$8.16K
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$2.15M -$26.8K -60,086 -23%
BCM
2
BlueCrest Capital Management
Jersey
$623K – – –
GCL
3
Glazer Capital LLC
New York
$365K -$8.16K -18,310 -2%
PAMP
4
Polar Asset Management Partners
Ontario, Canada
$166K – – –
AA
5
AQR Arbitrage
Connecticut
$132K – – –
6CM
6
683 Capital Management
New York
$102K – – –
Walleye Trading
7
Walleye Trading
New York
$89K +$1.45K +3,246 +2%
GCIA
8
Gabelli & Co Investment Advisers
New York
$73K -$22.7K -50,900 -26%
HF
9
HRT Financial
New York
$70K +$36.7K +82,224 +163%
RCM
10
Rivernorth Capital Management
Florida
$64K – – –
GF
11
Gabelli Funds
New York
$60K – – –
Walleye Capital
12
Walleye Capital
New York
$34K +$650 +1,458 +2%
BCM
13
Bluefin Capital Management
New York
$18K -$33.6K -75,307 Closed
WAM
14
Wolverine Asset Management
Illinois
$14K – – –
UBS Group
15
UBS Group
Switzerland
$6K +$2.62K +5,870 +90%
BCM
16
Basso Capital Management
Connecticut
– -$40K -85,600 Closed
PAM
17
Panagora Asset Management
Massachusetts
– -$1K -1,350 Closed

RVPHW Hedge Fund Activity: Q3 2020 in Review

14 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q3 2020, worth a combined $3.97M — down 12% from $4.51M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of RVPHW and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.

The largest buyer was HRT Financial, adding an estimated $36.7K. The largest seller was Basso Capital Management, exiting entirely with an estimated $40K sold.

  • 14 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q3 2020, down from 17 in Q2 2020.
  • Funds reported $3.97M of Reviva Pharmaceuticals Warrants stock for Q3 2020, down 12% quarter-over-quarter.
  • 0 funds opened new Reviva Pharmaceuticals Warrants positions in Q3 2020 and 3 closed out, a net change of -3 holders.
  • The largest Reviva Pharmaceuticals Warrants buyer in Q3 2020 was HRT Financial, an estimated $36.7K added.
  • The largest Reviva Pharmaceuticals Warrants seller in Q3 2020 was Basso Capital Management, an estimated $40K sold.

Based on aggregated 13F filings for Q3 2020.